Abstract:Human cytochrome P450 3A4 (hCYP3A4), one of the most important drug-metabolizing enzymes, catalyze the metabolic clearance of ∼50% therapeutic drugs. CYP3A4 inhibitors have been used for improving the in vivo efficacy of hCYP3A4-substrate drugs. However, most of existing hCYP3A4 inhibitors may trigger serious adverse effects or undesirable effects on endogenous metabolism. This study aimed to discover potent and orally active hCYP3A4 inhibitors from chalcone derivatives and to test their anti-hCYP3A4 effects both in vitro and in vivo. Following three rounds of screening and structural optimization, the isoquinoline chalcones were found with excellently anti-hCYP3A4 effects. SAR studies showed that introducing an isoquinoline ring on the A-ring significantly enhanced anti-CYP3A4 effect, generating A10 (IC50 = 102.10 nM) as a promising lead compound. The 2nd round of SAR studies showed that introducing a substituent group at the para position of the carbonyl group on B-ring strongly improved the anti-CYP3A4 effect. As a result, C6 was identified as the most potent hCYP3A4 inhibitor (IC50 = 43.93 nM) in human liver microsomes (HLMs). C6 also displayed potent anti-hCYP3A4 effect in living cells (IC50 = 153.00 nM), which was superior to the positive inhibitor ketoconazole (IC50 = 251.00 nM). Mechanistic studies revealed that C6 could potently inhibit CYP3A4-catalyzed N-ethyl-1,8-naphthalimide (NEN) hydroxylation in a competitive manner (Ki = 30.00 nM). Moreover, C6 exhibited suitable metabolic stability in HLMs and showed good safety profiles in mice. In vivo tests demonstrated that C6 (100 mg/kg, orally administration) significantly increased the AUC(0-inf) of midazolam by 3.63-fold, and strongly prolonged its half-life by 1.66-fold compared with the vehicle group in mice. Collectively, our findings revealed the SARs of chalcone derivatives as hCYP3A4 inhibitors and offered several potent chalcone-type hCYP3A4 inhibitors, while C6 could serve as a good lead compound for developing novel, orally active CYP3A4 inhibitors with improved druglikeness properties.

Development Of Benzochalcone Derivatives As Selective Cyp1b1 Inhibitors And Anticancer Agents

Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors

Discovery of 4'-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents

Design, Synthesis, anticancer evaluation and in silico studies of 2,4,6-trimethoxychalcone derivatives

Synthesis and Biological Evaluation of Novel Ligustrazine-Chalcone Derivatives As Potential Anti-Triple Negative Breast Cancer Agents

Inhibitors and Prodrugs Targeting Cyp1: A Novel Approach in Cancer Prevention and Therapy

Novel Benzothiazole, Benzimidazole and Benzoxazole Derivatives As Potential Antitumor Agents: Synthesis and Preliminary in Vitro Biological Evaluation

Discovery of Novel Steroidal-Chalcone Hybrids with Potent and Selective Activity Against Triple-Negative Breast Cancer.

Synthesis, biological evaluation and mechanism study of a class of benzylideneindanone derivatives as novel anticancer agents

Design, Synthesis, and Anticancer Activity of Novel Trimethoxyphenyl-Derived Chalcone-Benzimidazolium Salts

Design, Synthesis and Biological Evaluation of Chalcone Derivatives As Potent and Orally Active Hcyp3a4 Inhibitors.

Synthesis and Primary Evaluation of Quinoxalinone Derivatives As Potent Modulators of Multidrug Resistance

Synthesis and cytotoxic properties of novel (E)-3-benzylidene-7-methoxychroman-4-one derivatives

SYNTHESIS, In-vitro CYTOTOXICITY AND IN SILICO INVESTIGATIONS OF QUINAZOLINONE INTEGRATED CHALCONES: AS NOVEL POTENTIAL DUAL-TARGETING ANTICANCER AGENTS TO TREAT LUNG CANCER AND COLORECTAL CANCER

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.

Synthesis, Molecular Modeling and Biological Evaluation of Chalcone Thiosemicarbazide Derivatives As Novel Anticancer Agents.

Benzofuran‐chalcone derivatives as VEGFR‐2 inhibitors: synthesis and anticancer evaluation

Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity

Design, Synthesis and Biological Evaluation of Novel Hybrid Compounds of Imidazole Scaffold-Based 2-Benzylbenzofuran As Potent Anticancer Agents